AMGN

Amgen
D

AMGN

Arincen67/100B
463.79
USD
-2.77
(-0.59%)
Market Open
Last updated: · Delayed 15 min
Fair value366.70Plus+26%270Price 463.79665
Q4 FY2026 · Earnings report
EPS estimate 5.64Revenue estimate 10.45B
OverviewFinancialsNewsForecastEarningsDividendsCompany

Amgen revenue 1985–2026

Amgen's revenue in Q3 FY2026, the three months to 30 September 2026, was 10.37B USD, up 8.5% on the same quarter a year before. Amgen's revenue over the last twelve months was 38.93B USD, up 8.3% on the twelve months before. In fiscal year 2025 it was 36.74B USD, up 9.9% on the year before.

Last updated 12 Nov 2026 · Next report 2 Feb 2027

Revenue

Growth

Fiscal yearPeriod endingRevenueGrowthGross profitNet income
TTM30 Sept 202638.93B+8.27%28.80B9.39B
FY202531 Dec 202536.74B+9.92%26.01B7.71B
FY202431 Dec 202433.42B+18.57%20.57B4.09B
FY202331 Dec 202328.19B+7.09%19.78B6.72B
FY202231 Dec 202226.32B+1.32%19.92B6.55B
FY202131 Dec 202125.98B+2.18%19.53B5.89B
FY202031 Dec 202025.42B+8.83%19.27B7.26B
FY201931 Dec 201923.36B-1.62%19.01B7.84B
FY201831 Dec 201823.75B+3.93%19.65B8.39B
FY201731 Dec 201722.85B-0.62%18.78B1.98B
FY201631 Dec 201622.99B+6.14%18.83B7.72B
FY201531 Dec 201521.66B+7.97%17.44B6.94B
FY201431 Dec 201420.06B+7.43%15.64B5.16B
FY201331 Dec 201318.68B+8.17%15.33B5.08B
FY201231 Dec 201217.27B+10.80%14.35B4.35B
FY201131 Dec 201115.58B+3.51%13.16B3.68B
FY201031 Dec 201015.05B+2.81%12.83B4.63B
FY200931 Dec 200914.64B-2.41%12.55B4.61B
FY200831 Dec 200815.00B+1.57%12.71B4.20B
FY200731 Dec 200714.77B+3.53%12.22B3.17B
FY200631 Dec 200614.27B+14.79%12.17B2.95B
FY200531 Dec 200512.43B+17.82%10.35B3.67B
FY200431 Dec 200410.55B+26.26%8.82B2.36B
FY200331 Dec 20038.36B+51.29%7.02B2.26B
FY200231 Dec 20025.52B+37.54%4.79B-1.39B
FY200131 Dec 20014.02B+16.45%3.57B1.12B
FY200031 Dec 20003.45B+7.62%3.25B1.14B
FY199931 Dec 19993.20B+21.27%2.98B1.10B
FY199831 Dec 19982.64B+12.64%2.44B863.20M
FY199731 Dec 19972.35B+6.71%2.16B644.30M
FY199631 Dec 19962.20B+15.46%2.02B679.80M
FY199531 Dec 19951.90B+17.52%1.72B537.70M
FY199431 Dec 19941.62B+19.57%1.46B319.70M
FY199331 Dec 19931.35B+25.42%1.19B383.30M
FY199231 Dec 19921.08B+58.91%929.10M357.60M
FY199131 Dec 1991679.80M+257.04%588.60M97.90M
FY199031 Dec 1990190.40M+171.23%175.70M19.10M
FY198831 Dec 198870.20M+58.47%26.20M-8.20M
FY198731 Dec 198744.30M+48.66%8.80M1.70M
FY198631 Dec 198629.80M+41.23%8.00M800.00K
FY198531 Dec 198521.10M—23.60M500.00K

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Amgen revenue growth by segment

Q3 FY2026 against Q3 FY2025

Other Products1.73B
-6.5%
Repatha (evolocumab)1.09B
+36.6%
EVENITY751.00M
+38.8%
Prolia632.00M
-44.5%
ENBREL611.00M
+5.3%
TEZSPIRE538.00M
+42.7%
TEPEZZA526.00M
-6.1%
BLINCYTO496.00M
+26.5%
Product and Service, Other482.00M
+14.8%
Otezla481.00M
-17.8%
Nplate472.00M
+3.3%
KRYSTEXXA419.00M
+30.9%
Vectibix335.00M
+18.0%
Kyprolis330.00M
-8.1%
Aranesp329.00M
-7.8%
XGEVA288.00M
-46.6%

Amgen revenue by segment over time

Other Products Prolia Repatha Otezla ENBREL EVENITY XGEVA TEPEZZA Product and Service, Other BLINCYTO Nplate TEZSPIRE Aranesp KRYSTEXXA Vectibix EPOGEN Kyprolis NEUPOGEN Neulasta Sensipar Mimpara Repatha (evolocumab)
Fiscal yearOther ProductsProliaRepathaOtezlaENBRELEVENITYXGEVATEPEZZAProduct and Service, OtherBLINCYTONplateTEZSPIREAranespKRYSTEXXAVectibixEPOGENKyprolisNEUPOGENNeulastaSensipar MimparaRepatha (evolocumab)
FY20257.26B +29.0%4.41B +0.9%3.02B 2.27B +6.5%2.23B -32.9%2.10B +34.4%2.08B -6.3%1.90B +2.8%1.60B +14.7%1.56B +28.2%1.52B +4.7%1.48B +52.1%1.39B +3.5%1.34B +13.1%1.18B +12.4%— — — — — —
FY20245.63B +7.0%4.37B +8.1%— 2.13B -2.8%3.32B -10.3%1.56B +34.7%2.23B +5.4%1.85B +313.2%1.40B +9.2%1.22B +41.2%1.46B -1.4%972.00M 1.34B -1.5%1.19B +335.7%1.05B +6.2%— 1.50B +7.1%— — — 2.22B +35.9%
FY20235.26B -5.5%4.05B +11.6%— 2.19B -4.4%3.70B -10.2%1.16B +47.4%2.11B +4.9%448.00M 1.28B -15.9%861.00M 1.48B +13.0%— 1.36B -4.2%272.00M 984.00M — 1.40B +12.5%— — — 1.64B +26.2%
FY20225.57B -4.8%3.63B +11.7%— 2.29B +1.7%4.12B -7.8%787.00M 2.01B -0.2%— 1.52B -9.5%— 1.31B +27.3%— 1.42B -4.0%— — — 1.25B +12.5%— 1.13B -35.1%— 1.30B +16.0%
FY20215.85B -11.0%3.25B +17.6%— 2.25B +2.5%4.47B -10.6%— 2.02B +6.3%— 1.68B +42.1%— 1.03B — 1.48B -5.6%— — — 1.11B +4.0%— 1.73B -24.4%— 1.12B +25.9%
FY20206.57B +32.6%2.76B +3.4%— 2.20B 5.00B -4.4%— 1.90B -1.9%— 1.18B +2.2%— — — 1.57B -9.3%— — — 1.07B +2.0%— 2.29B -28.8%— 887.00M
FY20194.96B +15.2%2.67B +16.6%— — 5.23B +4.2%— 1.94B +8.3%— 1.16B -4.6%— — — 1.73B -7.9%— — 867.00M -14.2%1.04B — 3.22B -28.0%551.00M -68.9%—
FY20184.31B 2.29B +16.4%— — 5.01B -7.7%— 1.79B +13.4%— 1.21B — — — 1.88B -8.6%— — 1.01B -7.8%— — 4.48B -1.3%1.77B +3.3%—
FY2017— 1.97B +20.4%319.00M +126.2%— 5.43B -8.9%— 1.58B +3.0%— — 175.00M +52.2%642.00M +9.9%— 2.05B -1.9%— 642.00M +5.1%1.10B -14.5%835.00M +20.7%549.00M -28.2%4.53B -2.5%1.72B +8.6%—
FY2016— 1.64B +24.6%141.00M — 5.97B +11.2%— 1.53B +8.8%— — 115.00M 584.00M +11.2%— 2.09B +7.3%— 611.00M +11.3%1.28B -30.9%692.00M +35.2%765.00M -27.1%4.65B -1.4%1.58B +11.8%—

See also:Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Amgen's revenue

Source: Financial Modeling PrepVerified against SEC filings